Impala Nordic has published a coverage comment on OncoZenge AB (publ) following the company's interim report for the third quarter of 2026.The quarter changed the company's financial position. Cash rose from SEK 0.7m at the half-year mark to SEK 24.3m and the equity ratio from 36.5 to 55.3 percent, after a rights issue subscribed to approximately 92 percent in which the guarantee was never called. Sichuan Yangtian subscribed for its full pro rata entitlement and remains the largest owner at 19.7 percent.Nine hospitals are now recruiting in the pivotal Phase III BEAM-Pain trial, and the company has received several written, non-binding offers from potential licensees ahead of the readout. Recruitment has run slower than planned, and completion of the trial has moved into 2027.

Click here to read the report comment

For additional information, please contact:

Ylber Rexhepi, CEO Impala Nordicylber@impalanordic.se

About Impala Nordic

Impala Nordic provides equity research, coverage, and comprehensive investor relations (IR) services. The portfolio includes listed small-cap companies, where Impala Nordic acts as a communicative bridge between the companies and investors.

The material produced by Impala Nordic is independent but sponsored. This means that Impala Nordic has received payment from the client to produce the analysis and coverage. The client has not been able to influence Impala Nordic’s opinions expressed in the material.

Bifogade filer

OncoZenge Report Comment 2026 11 12